Data from 89bio's enliven phase 2b trial of pegozafermin in patients with nonalcoholic steatohepatitis (nash) published in the new england journal of medicine and simultaneously presented in a late-breaker session at the easl international liver congress

– enliven results demonstrated that treatment with pegozafermin 30mg weekly and 44mg every-two-week doses resulted in statistically significant changes on both primary histology endpoints –

ETNB Ratings Summary

ETNB Quant Ranking